Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies

被引:0
|
作者
Rubin, David T. [1 ]
Wolf, Douglas C. [2 ]
Alekseeva, Olga [3 ]
Charles, Lorna [4 ]
Afsari, Sonia [4 ]
Petersen, Ann Katrin [5 ]
Sheffield, James [4 ]
Li, Hongjuan [4 ]
Silva, Diego [4 ]
Lublin, Fred D. [6 ]
Cree, Bruce [7 ]
Cohen, Jeffrey [8 ]
Danese, Silvio [9 ]
机构
[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA
[2] Atlanta Gastroenterol Associates, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA
[3] Nizhni Novgorod Reg Clin Hosp, Nizhnii Novgorod, Nizhegorod, Russia
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Bristol Myers Squibb, Princeton, CA USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA
[8] Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH USA
[9] Humanitas Clin & Res Ctr IRCCS & Hunimed, Ctr Inflammatory Bowel Dis, Milan, Lombardia, Italy
来源
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
S853
引用
收藏
页码:S396 / S396
页数:1
相关论文
共 50 条
  • [1] Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
    Rubin, David T.
    Cree, Bruce A. C.
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Petersen, AnnKatrin
    Sheffield, James K.
    Cheng, Chun-Yen
    Riolo, Jon V.
    Silva, Diego
    Lublin, Fred D.
    Cohen, Jeffrey A.
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S680 - S680
  • [2] Long-term Safety of Ozanimod in Relapsing Multiple Sclerosis and Moderately to Severely Active Ulcerative Colitis
    Cree, Bruce A. C.
    Danese, Silvio
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Petersen, AnnKatrin
    Sheffield, James K.
    Cheng, Chun-Yen
    Riolo, Jon V.
    Silva, Diego
    Lublin, Fred D.
    Rubin, David T.
    Cohen, Jeffrey A.
    NEUROLOGY, 2023, 100 (17)
  • [3] Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
    Danese, S.
    Colombel, J. F.
    Ponich, T.
    Jovanovic, I.
    Bossuyt, P.
    Longman, R.
    Alekseeva, O.
    Petersen, A.
    Chitkara, D.
    Marta, C.
    Charles, L.
    Rubin, D. T.
    Afzali, A.
    Loftus, E. V.
    Wolf, D. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I093 - I094
  • [4] LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Wolf, Douglas C.
    Colombel, Jean Frederic
    Ponich, Terry P.
    Jovanovic, Igor
    Bossuyt, Peter
    Longman, Randy
    Alekseeva, Olga
    Petersen, AnnKatrin
    Chitkara, Denesh
    Marta, Cecilia
    Charles, Lorna
    Rubin, David T.
    Afzali, Anita
    Loftus, Edward V.
    Danese, Silvio
    GASTROENTEROLOGY, 2022, 162 (07) : S969 - S969
  • [5] Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis
    Danese, S.
    Colombel, J-F
    Ponich, T.
    Jovanovic, I.
    Bossuyt, P.
    Longman, R.
    Alekseeva, O.
    Petersen, A. K.
    Marta, C.
    Charles, L.
    Sparrow, M.
    Rubin, D. T.
    Afzali, A.
    Loftus, E. V., Jr.
    Wolf, D. C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 125 - 126
  • [6] Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
    Millie, Long
    Raymond, Cross
    Jonathan, Calkwood
    Marc, Pondel
    Ashwini, Pai
    Harris, Ahmad
    Lorna, Charles
    Ayanbola, Elegbe
    AnnKatrin, Petersen
    James, Sheffield
    Adil, Javed
    Douglas, Wolf
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S9 - S10
  • [7] Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis
    Armuzzi, A.
    Cross, R. K.
    Lichtenstein, G.
    Calkwood, J.
    Pai, A.
    Pondel, M.
    Ahmad, H. A.
    Charles, L.
    Elegbe, A.
    Petersen, A.
    Sheffield, J. K.
    Javed, A.
    Hou, J.
    Regueiro, M.
    Wolf, D. C.
    Long, M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I094 - I095
  • [8] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla C.
    Betts, Keith
    Eren, Devrim
    Tang, Wenxi
    Yin, Lei
    Gupte-Singh, Komal
    GASTROENTEROLOGY, 2022, 162 (07) : S603 - S603
  • [9] Long-term cardiac safety of ozanimod in Phase 3 clinical program of ulcerative colitis and relapsing multiple sclerosis
    Armuzzi, A.
    Cross, R. K.
    Lichtenstein, G. R.
    Calkwood, J.
    Ahmad, H. A.
    Charles, L.
    Elegbe, A.
    Petersen, A. K.
    Sheffield, J. K.
    Sparrow, M.
    Javed, A.
    Hou, J.
    Regueiro, M.
    Wolf, D. C.
    Long, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 126 - 127
  • [10] LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS
    Long, Millie D.
    Cross, Raymond K.
    Lichtenstein, Gary R.
    Calkwood, Jonathan
    Pai, Ashwini
    Pondel, Marc
    Ahmad, Harris
    Charles, Lorna
    Elegbe, Ayanbola
    Petersen, AnnKatrin
    Sheffield, James K.
    Javed, Adil
    Hou, Jason K.
    Regueiro, Miguel D.
    Wolf, Douglas C.
    Armuzzi, Alessandro
    GASTROENTEROLOGY, 2022, 162 (07) : S5 - S6